Loading
EI
Endo International plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Coleman Blaise, was filed 15 Aug 2017.
Endo International plc: what insiders have been doing
Endo International plc, founded in 1997, is a Healthcare & Pharma company based in Ireland, Ireland. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Endo International plc. The previous disclosure was published on 17 August 2022.
The full history, which starts in 2016, counts 15 purchases against 21 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
399
Thresholds
n/a
Buy Volume
€954,416
15 ops. · all time
Sell Volume
€2M
21 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$1.7B
Net income-US$2.1B-121.8% margin
Last declaration on 17 August 2022
Declarations399 total
280,373 shares2015 Stock Incentive Plan Restricted Stock Units (RSU)SEC:0001593034-22-000059:0
10,179 shares@ US$2.521.9% of flowOrdinary SharesSEC:0001593034-22-000030:3
10,137 shares@ US$2.521.8% of flowOrdinary SharesSEC:0001593034-22-000028:3
3,057 shares@ US$2.523.7% of flowOrdinary SharesSEC:0001593034-22-000029:3
42,341 shares0Stock Incentive Plan Performance Share UnitsSEC:0001593034-22-000032:1
16,957 shares0Ordinary SharesSEC:0001593034-22-000032:2
89,663 shares0Stock Incentive Plan Performance Share UnitsSEC:0001593034-22-000028:1
35,910 shares0Ordinary SharesSEC:0001593034-22-000028:2
26,805 shares0Stock Incentive Plan Performance Share UnitsSEC:0001593034-22-000029:1
10,735 shares0Ordinary SharesSEC:0001593034-22-000029:2
85,927 shares0Stock Incentive Plan Performance Share UnitsSEC:0001593034-22-000030:1
34,414 shares0Ordinary SharesSEC:0001593034-22-000030:2
4,975 shares@ US$2.522.3% of flowOrdinary SharesSEC:0001593034-22-000032:3
965 shares@ US$2.5272.4% of flowOrdinary SharesSEC:0001593034-22-000031:0
2,544 shares@ US$2.5226.0% of flowOrdinary SharesSEC:0001593034-22-000029:0
4,141 shares@ US$2.5236.1% of flowOrdinary SharesSEC:0001593034-22-000032:0
8,472 shares@ US$2.5249.9% of flowOrdinary SharesSEC:0001593034-22-000030:0
8,437 shares@ US$2.5222.1% of flowOrdinary SharesSEC:0001593034-22-000028:0
9,120 shares@ US$2.342550.1% of flowOrdinary SharesSEC:0001593034-22-000018:0
394 shares@ US$2.342527.6% of flowOrdinary SharesSEC:0001593034-22-000021:0
7,853 shares@ US$2.342563.9% of flowOrdinary SharesSEC:0001593034-22-000022:0
31,886 shares@ US$2.342577.9% of flowOrdinary SharesSEC:0001593034-22-000019:0
7,789 shares@ US$2.342574.0% of flowOrdinary SharesSEC:0001593034-22-000020:0
23,003 shares@ US$6.2676.1% of flowOrdinary SharesSEC:0001593034-21-000077:1
23,003 shares@ US$6.2615.3% of flowOrdinary SharesSEC:0001593034-21-000079:1
25 of 399 declarations
About Endo International plc
Endo International plc was historically a U.S.-listed specialty pharmaceutical company traded on the NASDAQ under ticker ENDP, with operations centered in the United States. The company was incorporated in Ireland in 2013 and re-registered as a public limited company in 2014, while maintaining key corporate and operational footprints in Malvern, Pennsylvania, and Dublin, Ireland. Its business model combined branded specialty pharmaceuticals with a meaningful generics platform, with particular exposure to sterile injectables, hospital-focused aseptic medicines, and selected branded therapies for niche medical conditions. ([endo.com](https://www.endo.com/company/contact-locations/?utm_source=openai))
From an industry perspective, Endo occupied a middle-ground position in healthcare: more differentiated than a pure generics manufacturer, but not a broad-based large-cap innovator. The company emphasized capabilities in development, manufacturing, and commercialization, and highlighted product categories such as sterile injectables, aseptic products, and ready-to-administer/ready-to-use formulations. Its portfolio was designed to serve hospitals, specialists, and pharmaceutical distribution channels, with a focus on value-added products where operational reliability, quality, and regulatory execution matter as much as pricing. ([endo.com](https://www.endo.com/products-and-capabilities/products/?utm_source=openai))
Read moreShow less
Geographically, Endo was predominantly U.S.-oriented, with the United States as its core commercial market and manufacturing base, complemented by operations in Ireland and India. The company maintained multiple U.S. facilities across Pennsylvania, New Jersey, New York, and Michigan, reflecting a supply chain built to support domestic healthcare demand. For investors, Endo should be viewed as a complex turnaround and restructuring story rather than a conventional growth pharma name, particularly given its long-running litigation, regulatory, and balance-sheet challenges. ([endo.com](https://www.endo.com/company/contact-locations/?utm_source=openai))
A major recent development materially changed the company’s identity. In July 2025, Endo and Mallinckrodt completed a merger, after which the combined company spun off its generics and sterile injectables business as an independent company, Par Health, and later rebranded the specialty therapeutics business as Keenova Therapeutics in November 2025. As a result, the historic Endo International plc profile is now largely a legacy reference point, but it remains relevant for interpreting SEC filings, including Form 4 insider transaction activity, and for understanding the company’s evolution in the U.S. healthcare sector. ([endo.com](https://www.endo.com/?utm_source=openai))
